Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ALS
ALS
Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program
Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program
Fierce Biotech
VectorY Therapeutics
funding
ALS
Merck
Flag link:
BrainStorm lays off 30% of staff, slimming down for yet another bid to get ALS cell therapy to market
BrainStorm lays off 30% of staff, slimming down for yet another bid to get ALS cell therapy to market
Fierce Biotech
BrainStorm Cell Therapeutics
layoffs
FDA
ALS
NurOwn
Flag link:
BrainStorm eyes FDA meeting to find path for rejected ALS drug after withdrawing application
BrainStorm eyes FDA meeting to find path for rejected ALS drug after withdrawing application
Fierce Biotech
BrainStorm Cell Therapeutics
ALS
FDA
NurOwn
Flag link:
Amylyx’s ALS drug knocked back again in Europe
Amylyx’s ALS drug knocked back again in Europe
BioPharma Dive
Amylyx Pharmaceuticals
ALS
Europe
Flag link:
FDA Adcomm Rejects BrainStorm’s ALS Therapy in Nearly Unanimous Vote
FDA Adcomm Rejects BrainStorm’s ALS Therapy in Nearly Unanimous Vote
BioSpace
BrainStorm Cell Therapeutics
FDA
ALS
NurOwn
Flag link:
AcuraStem and Takeda Partner to Revolutionize ALS Treatment
AcuraStem and Takeda Partner to Revolutionize ALS Treatment
Best Stocks
Takeda
AcuraStem
ALS
AS-202
Flag link:
FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show
FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show
BioPharma Dive
Brainstorm Cell Thearpaueics
ALS
stem cells
FDA
NurOwn
Flag link:
ALS advocates say criticism of new drugs misses bigger picture
ALS advocates say criticism of new drugs misses bigger picture
Stat
ALS
drug development
Flag link:
Clene polishes tarnished ALS asset with long-term survival data
Clene polishes tarnished ALS asset with long-term survival data
Fierce Biotech
Clene
ALS
clinical trials
CNM-Au8
Flag link:
Amylyx ALS drug sales tick higher after fast US launch
Amylyx ALS drug sales tick higher after fast US launch
BioPharma Dive
Amylx
earnings
ALS
Flag link:
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
Flag link:
Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker
Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker
Fierce Biotech
BrainStorm Cell Therapeutics
ALS
cell therapy
Biogen
NurOwn
Flag link:
EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's ALS Treatment
EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's ALS Treatment
Benzinga
Amylyx Pharmaceuticals
ALS
Albrioza
EMA
Europe
Flag link:
Biogen teams with NeuroSense to explore ALS neurofilament biomarker
Biogen teams with NeuroSense to explore ALS neurofilament biomarker
BioSpace
Biogen
NeuroSense Therapeutics
ALS
PrimeC
Flag link:
How ALS Cell Models That Began In Blood Spurred An Encouraging Early-Stage Clinical Trial
How ALS Cell Models That Began In Blood Spurred An Encouraging Early-Stage Clinical Trial
Forbes
clinical trials
innovation
ALS
Parkinson's Disease
Biogen
Flag link:
FDA sets advisory meeting date for Brainstorm’s ALS cell therapy
FDA sets advisory meeting date for Brainstorm’s ALS cell therapy
BioPharma Dive
BrainStorm Cell Therapeutics
FDA
NurOwn
cell therapy
ALS
Flag link:
Quanterix sees a bright future for blood biomarkers
Quanterix sees a bright future for blood biomarkers
EP Vantage
Biogen
Quanterix
diagnostics
Qalsody
ALS
biomarkers
Flag link:
Amylyx’s ALS drug could face rejection in Europe
Amylyx’s ALS drug could face rejection in Europe
BioPharma Dive
Amylyx
ALS
EMA
Europe
Relyvrio
Flag link:
Apellis abandons ALS drug after study miss
Apellis abandons ALS drug after study miss
BioPharma Dive
Apellis Pharmaceuticals
ALS
clinical trials
pegcetacoplan
Flag link:
Wave's ALS-dementia drug crashes out after early-phase flop, dealing further blow to target
Wave's ALS-dementia drug crashes out after early-phase flop, dealing further blow to target
Fierce Biotech
Wave Life Sciences
antisense
WVE-004
clinical trials
ALS
dementia
Flag link:
Pages
1
2
3
4
5
6
7
8
9
next ›
last »